<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02229097</url>
  </required_header>
  <id_info>
    <org_study_id>13 7029 08</org_study_id>
    <secondary_id>2014-000969-47</secondary_id>
    <secondary_id>13-074</secondary_id>
    <nct_id>NCT02229097</nct_id>
  </id_info>
  <brief_title>Efficacy of Coordinated Insulin Boluses in Type 1 Diabetic Patients</brief_title>
  <acronym>COBOL</acronym>
  <official_title>Clinical Efficacy of Coordinated Boluses in Type 1 Diabetic Patients Treated With Insulin Pumps: a Multicentric, Randomised, Cross Over Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A recent study suggests that, in Type 1 Diabetes (T1D) patients treated by insulin pumps, a
      better coordination of meal boluses and post prandial basal rate could reduce the importance
      of postprandial hyperglycaemias without increasing the risk of delayed hypoglycaemias.

      The aim of the investigators study is to assess if these results are confirmed in a clinical
      trial.

      The aim of this study is to compare the efficacy of coordinated boluses versus normal boluses
      on postprandial glycaemic control of T1D patients treated with continuous subcutaneous
      insulin infusion.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2014</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postprandial glycaemia</measure>
    <time_frame>2 hours after eating during 4 weeks</time_frame>
    <description>measured by Self Monitoring of Blood Glucose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>Throughout the study (4 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>severe hypoglycaemia frequency</measure>
    <time_frame>Throughout the study (4 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin doses</measure>
    <time_frame>basal rate and boluses</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean glycaemia</measure>
    <time_frame>before eating and 2 hours after eating during 4 weeks</time_frame>
    <description>data from Self Monitoring of Blood Glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>standard deviation of glycaemia</measure>
    <time_frame>before eating and 2 hours after eating during 4 weeks</time_frame>
    <description>data from Self Monitoring of Blood Glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency of glycaemia &lt; or = 60mg/dl</measure>
    <time_frame>before eating and 2 hours after eating during 4 weeks</time_frame>
    <description>data from Self Monitoring of Blood Glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency of glycaemia between 61-140mg/dl</measure>
    <time_frame>before eating and 2 hours after eating during 4 weeks</time_frame>
    <description>data from Self Monitoring of Blood Glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency of glycaemia &gt;140mg/dl</measure>
    <time_frame>before eating and 2 hours after eating during 4 weeks</time_frame>
    <description>data from Self Monitoring of Blood Glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean glycemia</measure>
    <time_frame>Throughout the day during 4 weeks</time_frame>
    <description>data from Continue Glycemia Monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>standard deviation</measure>
    <time_frame>Throughout the day during 4 weeks</time_frame>
    <description>data from Continue Glycemia Monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time spent within glucose range &lt; or = 60mg/dl</measure>
    <time_frame>Throughout the day during 4 weeks</time_frame>
    <description>data from Continue Glycemia Monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time spent within glucose range between 61-140mg/dl</measure>
    <time_frame>Throughout the day during 4 weeks</time_frame>
    <description>data from Continue Glycemia Monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time spent within glucose range mg/dl</measure>
    <time_frame>Throughout the day during 4 weeks</time_frame>
    <description>data from Continue Glycemia Monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fructosamine</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fructosamine</measure>
    <time_frame>day 1 + 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fructosamine</measure>
    <time_frame>day 1 + 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Normal then Coordinated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>normal bolus during 2 weeks then coordinated bolus during 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Coordinated then Normal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>coordinated bolus during 2 weeks then normal bolus during 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal bolus</intervention_name>
    <description>During the &quot;normal bolus&quot; period, the bolus will be adjusted to the carbohydrate content of each meal and injected immediately. The basal rate will remain at a normal level during the 3 hours postprandial period</description>
    <arm_group_label>Normal then Coordinated</arm_group_label>
    <arm_group_label>Coordinated then Normal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Coordinated bolus</intervention_name>
    <description>The basal rate will be reduced at a rate of 0.1 U/h during the 3 h postprandial period. The insulin subtracted of the basal rate will be added to the normal bolus calculated for the meal and injected immediately.</description>
    <arm_group_label>Normal then Coordinated</arm_group_label>
    <arm_group_label>Coordinated then Normal</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 diabetes mellitus

          -  with confirmed Negative C-peptide or diabetes duration&gt;5 years

          -  Treated by external insulin pump and rapid insulin analog for more than 3 months

          -  using a Medtronic Paradigm Real-Time or Veo™ model

          -  Educated to and practicing functional insulin treatment and carbohydrate counting for
             more than 3 months

          -  Able to use the &quot;basal temp&quot; and &quot;glycaemia reminder&quot; functions of their pump

          -  Basal infusion rate ≥ 0,5 Unit/h

          -  Self-monitoring of blood glucose frequency &gt; 4/days

          -  Aware of hypoglycaemia

        Exclusion Criteria:

          -  known impaired renal function (creatinin clearance &lt;60ml/min)

          -  Gastroparesis

          -  Serious or instable disease likely to induce a glycaemic control deterioration -
             treatment with corticosteroids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent Melki, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Toulouse Rangueil</name>
      <address>
        <city>Toulouse</city>
        <state>Haute Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-André Hospital</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lapeyronie Hospital</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Bondia J, Dassau E, Zisser H, Calm R, Vehí J, Jovanovič L, Doyle FJ 3rd. Coordinated basal-bolus infusion for tighter postprandial glucose control in insulin pump therapy. J Diabetes Sci Technol. 2009 Jan;3(1):89-97.</citation>
    <PMID>20046653</PMID>
  </reference>
  <reference>
    <citation>A. Farret, B. Catargi, J.P. Riveline, V. Melki, P. Schaepelynck, A. Sola, B. Guerci, H. Bertet, T. Mura, H. Chevassus, E. Renard : Étude randomisée contrôlée en cross-over comparant les effets sur le contrôle glycémique des bolus immédiats et combinés chez des patients diabétiques de type 1 traités par pompe à insuline portable. Diabetes &amp; Metabolism, Volume 38, Supplement 2, March 2012, Page A6</citation>
  </reference>
  <reference>
    <citation>Druet C, Roudier C, Romon I, Assogba F, Bourdel-Marchasson I, et al. Échantillon national témoin représentatif des personnes diabétiques, Entred 2007-2010.</citation>
  </reference>
  <reference>
    <citation>Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, Rand L, Siebert C. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 Sep 30;329(14):977-86.</citation>
    <PMID>8366922</PMID>
  </reference>
  <reference>
    <citation>Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005 Dec 22;353(25):2643-53.</citation>
    <PMID>16371630</PMID>
  </reference>
  <reference>
    <citation>Etude Jubilé. SFD 2013</citation>
  </reference>
  <reference>
    <citation>Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ. 2002 Mar 23;324(7339):705.</citation>
    <PMID>11909787</PMID>
  </reference>
  <reference>
    <citation>Mudaliar SR, Lindberg FA, Joyce M, Beerdsen P, Strange P, Lin A, Henry RR. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care. 1999 Sep;22(9):1501-6.</citation>
    <PMID>10480516</PMID>
  </reference>
  <reference>
    <citation>Directive pour la gestion de la glycémie post prandiale, IDF 2007 http://www.idf.org/webdata/docs/French_GMPG Final 110108.pdf</citation>
  </reference>
  <reference>
    <citation>Melki.v, Cazals.l : Impact de la coordination des bolus et du débit de base sur le contrôle des glycémies postprandiales chez des diabétiques de type 1 traités par pompe externe (étude pilote). Poster accepté SFD 2014</citation>
  </reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2014</study_first_submitted>
  <study_first_submitted_qc>August 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2014</study_first_posted>
  <last_update_submitted>February 21, 2017</last_update_submitted>
  <last_update_submitted_qc>February 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>type 1 diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

